Beijing Cancer hospital-Thoracic Cancer Department A ( Site 2003)

Beijing, Beijing Municipality 100142

0 studies enrolling now · 1 studies all time

What they study most

Lung Neoplasms, Non-Small-Cell Lung Carcinoma

Studies at this site

• Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003) — Completed